A vesicular stomatitis virus replicon-based bioassay for the rapid and sensitive determination of multi-species type I interferon

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Rentsch, Marianne Berger ^a   Zimmer, Gert ^a  

^a INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; FIREFLY LUCIFERASE; GAMMA INTERFERON; GLYCOPROTEIN; GREEN FLUORESCENT PROTEIN; INTERLEUKIN 29; PROTEIN G; RECOMBINANT INTERFERON; VIRUS VECTOR;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; BIOASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG DETERMINATION; FIBROBLAST; HUMAN; HUMAN CELL; INFECTION SENSITIVITY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REPLICON; SENSITIVITY ANALYSIS; VESICULAR STOMATITIS VIRUS; VIRUS ENVELOPE;

ANIMALS; ANTIVIRAL AGENTS; BIOLOGICAL ASSAY; CELL LINE, TUMOR; DOGS; GENES, REPORTER; GREEN FLUORESCENT PROTEINS; HUMANS; HYDROGEN-ION CONCENTRATION; INTERFERON TYPE I; LUCIFERASES, FIREFLY; MICE; PROTEIN STABILITY; REPLICON; SAFETY; SPECIES SPECIFICITY; TEMPERATURE; TIME FACTORS; VESICULOVIRUS;

AVES; HEPATITIS C VIRUS; MAMMALIA; SUS; VESICULAR STOMATITIS VIRUS;

EID: 80053593989     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025858     Document Type: Article

References (36)

1. Der SD, Zhou A, Williams BR, Silverman RH, (1998) Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci U S A 95: 15623-15628.
2. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, et al. (2011) A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472: 481-485.
3. Sadler AJ, Williams BR, (2008) Interferon-inducible antiviral effectors. Nat Rev Immunol 8: 559-568.
4. Maher SG, Romero-Weaver AL, Scarzello AJ, Gamero AM, (2007) Interferon: cellular executioner or white knight? Curr Med Chem 14: 1279-1289.
5. Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, et al. (2003) Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 424: 516-523.
6. Vosoughi R, Freedman MS, (2010) Therapy of MS. Clin Neurol Neurosurg 112: 365-385.
7. Tsubota A, Fujise K, Namiki Y, Tada N, (2011) Peginterferon and ribavirin treatment for hepatitis C virus infection. World J Gastroenterol 17: 419-432.
8. Ferrantini M, Capone I, Belardelli F, (2007) Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie 89: 884-893.
9. Rizza P, Moretti F, Belardelli F, (2010) Recent advances on the immunomodulatory effects of IFN-alpha: implications for cancer immunotherapy and autoimmunity. Autoimmunity 43: 204-209.
10. Malucchi S, Gilli F, Caldano M, Sala A, Capobianco M, et al. (2011) One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients. J Neurol 258: 895-903.
11. Sommereyns C, Paul S, Staeheli P, Michiels T, (2008) IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 4: e1000017.
12. Mordstein M, Neugebauer E, Ditt V, Jessen B, Rieger T, et al. (2010) Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J Virol 84: 5670-5677.
13. Pott J, Mahlakoiv T, Mordstein M, Duerr CU, Michiels T, et al. (2011) IFN-lambda determines the intestinal epithelial antiviral host defense. Proc Natl Acad Sci U S A 108: 7944-7949.
14. Meager A, (2002) Biological assays for interferons. J Immunol Methods 261: 21-36.
15. Perler L, Pfister H, Schweizer M, Peterhans E, Jungi TW, (1999) A bioassay for interferon type I based on inhibition of Sendai virus growth. J Immunol Methods 222: 189-196.
16. Park MS, Shaw ML, Munoz-Jordan J, Cros JF, Nakaya T, et al. (2003) Newcastle disease virus (NDV)-based assay demonstrates interferon-antagonist activity for the NDV V protein and the Nipah virus V, W, and C proteins. J Virol 77: 1501-1511.
17. Kopecky-Bromberg SA, Martinez-Sobrido L, Frieman M, Baric RA, Palese P, (2007) Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists. J Virol 81: 548-557.
18. Valmas C, Grosch MN, Schumann M, Olejnik J, Martinez O, et al. (2010) Marburg virus evades interferon responses by a mechanism distinct from ebola virus. PLoS Pathog 6: e1000721.
19. Kuri T, Habjan M, Penski N, Weber F, (2010) Species-independent bioassay for sensitive quantification of antiviral type I interferons. Virol J 7: 50.
20. Vrolijk JM, Kaul A, Hansen BE, Lohmann V, Haagmans BL, et al. (2003) A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C. J Virol Methods 110: 201-209.
21. Larocque L, Bliu A, Xu R, Diress A, Wang J, et al. (2011) Bioactivity determination of native and variant forms of therapeutic interferons. J Biomed Biotechnol 2011.
22. Schwarz H, Harlin O, Ohnemus A, Kaspers B, Staeheli P, (2004) Synthesis of IFN-beta by virus-infected chicken embryo cells demonstrated with specific antisera and a new bioassay. J Interferon Cytokine Res 24: 179-184.
23. Hanika A, Larisch B, Steinmann E, Schwegmann-Wessels C, Herrler G, et al. (2005) Use of influenza C virus glycoprotein HEF for generation of vesicular stomatitis virus pseudotypes. J Gen Virol 86: 1455-1465.
24. Balmelli C, Vincent IE, Rau H, Guzylack-Piriou L, McCullough K, et al. (2005) Fc gamma RII-dependent sensitisation of natural interferon-producing cells for viral infection and interferon-alpha responses. Eur J Immunol 35: 2406-2415.
25. Schultz U, Rinderle C, Sekellick MJ, Marcus PI, Staeheli P, (1995) Recombinant chicken interferon from Escherichia coli and transfected COS cells is biologically active. Eur J Biochem 229: 73-76.
26. Rothlisberger A, Wiener D, Schweizer M, Peterhans E, Zurbriggen A, et al. (2010) Two domains of the V protein of virulent canine distemper virus selectively inhibit STAT1 and STAT2 nuclear import. J Virol 84: 6328-6343.
27. Schnell MJ, Buonocore L, Whitt MA, Rose JK, (1996) The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus. J Virol 70: 2318-2323.
28. Kalhoro NH, Veits J, Rautenschlein S, Zimmer G, (2009) A recombinant vesicular stomatitis virus replicon vaccine protects chickens from highly pathogenic avian influenza virus (H7N1). Vaccine 27: 1174-1183.
29. Bloor S, Maelfait J, Krumbach R, Beyaert R, Randow F, (2010) Endoplasmic reticulum chaperone gp96 is essential for infection with vesicular stomatitis virus. Proc Natl Acad Sci U S A 107: 6970-6975.
30. Hoffmann M, Wu YJ, Gerber M, Berger-Rentsch M, Heimrich B, et al. (2010) Fusion-active glycoprotein G mediates the cytotoxicity of vesicular stomatitis virus M mutants lacking host shut-off activity. J Gen Virol 91: 2782-2793.
31. Jariwalla R, Grossberg SE, Sedmak JJ, (1975) The influence of physicochemical factors on the thermal inactivation of murine interferon. Arch Virol 49: 261-272.
32. Taylor-Papadimitriou J, Stoker M, (1971) Effect of interferon on some aspects of transformation by polyoma virus. Nat New Biol 230: 114-117.
33. Faria PA, Chakraborty P, Levay A, Barber GN, Ezelle HJ, et al. (2005) VSV disrupts the Rae1/mrnp41 mRNA nuclear export pathway. Mol Cell 17: 93-102.
34. Randall RE, Goodbourn S, (2008) Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol 89: 1-47.
35. Virelizier JL, Allison AC, de Maeyer E, (1977) Production by mixed lymphocyte cultures of a type II interferon able to protect macrophages against virus infection. Infect Immun 17: 282-285.
36. Isaacs A, Lindenmann J, (1957) Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 147: 258-267.